{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:29:26Z","timestamp":1769041766906,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T00:00:00Z","timestamp":1488931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jval.2017.02.001","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T10:27:43Z","timestamp":1519208863000},"page":"185-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Comparison of Different Approaches for Costing Medication Use in an Economic Evaluation"],"prefix":"10.1016","volume":"21","author":[{"given":"Margaret","family":"Heslin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwagbemisola","family":"Babalola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fowzia","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Stringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2017.02.001_bib1","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005"},{"key":"10.1016\/j.jval.2017.02.001_bib2","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. 2013. Available from: http:\/\/publications.nice.org.uk\/pmg9. [Accessed February 20, 2016]."},{"key":"10.1016\/j.jval.2017.02.001_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-4733.2009.00663.x","article-title":"Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force Report\u2014part I","volume":"13","author":"Hay","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2017.02.001_bib4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00019053-199915060-00007","article-title":"Cost of schizophrenia to UK society","volume":"15","author":"Guest","year":"1999","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2017.02.001_bib5","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2165\/00019053-200826100-00005","article-title":"Multiple sclerosis in the UK","volume":"26","author":"McCrone","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2017.02.001_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.spinee.2007.10.005","article-title":"A systematic review of low back pain cost of illness studies in the United States and internationally","volume":"8","author":"Dagenais","year":"2008","journal-title":"Spine J"},{"key":"10.1016\/j.jval.2017.02.001_bib7","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1136\/gut.2004.041616","article-title":"Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study","volume":"53","author":"Bassi","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.jval.2017.02.001_bib8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/heart.88.6.597","article-title":"The economic burden of coronary heart disease in the UK","volume":"88","author":"Liu","year":"2002","journal-title":"Heart"},{"key":"10.1016\/j.jval.2017.02.001_bib9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1610-0387.2005.05729.x","article-title":"Cost of illness in patients with moderate and severe chronic psoriasis vulgaris in Germany","volume":"3","author":"Berger","year":"2005","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jval.2017.02.001_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40273-012-0001-x","article-title":"Operationalizing value-based pricing of medicines: a taxonomy of approaches","volume":"31","author":"Sussex","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2017.02.001_bib11","doi-asserted-by":"crossref","first-page":"h1046","DOI":"10.1136\/bmj.h1046","article-title":"Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial","volume":"350","author":"Scott","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2017.02.001_bib12","article-title":"Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews","volume":"8","author":"Scott","year":"2014","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2017.02.001_bib13","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the Panel on Cost-Effectiveness in Health and Medicine","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2017.02.001_bib14","series-title":"British National Formulary 60","year":"2010"},{"key":"10.1016\/j.jval.2017.02.001_bib15","unstructured":"Department of Health. Prescription cost analysis\u2014England, 2011. 2011. Available from: www.hscic.gov.uk\/pubs\/prescostanalysis2011. [Accessed February 1, 2016]."},{"key":"10.1016\/j.jval.2017.02.001_bib16","doi-asserted-by":"crossref","unstructured":"McCrone P, Payan CA, Knapp M, et al. The economic costs of progressive supranuclear palsy and multiple system atrophy in France, Germany and the United Kingdom. PLoS One 20118;6:e24369.","DOI":"10.1371\/journal.pone.0024369"},{"key":"10.1016\/j.jval.2017.02.001_bib17","doi-asserted-by":"crossref","unstructured":"Powell C, Kolamunnage-Dona R, Lowe J, et al; MAGNETIC Study Group. Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial. Lancet Respir Med 2013;1:301\u20138","DOI":"10.1016\/S2213-2600(13)70037-7"},{"key":"10.1016\/j.jval.2017.02.001_bib18","unstructured":"Amiel SA, Ismail K, Winkley K, et al. Non-pharmacological approaches to improving diabetes outcomes. Health Serv Deliv Res. In press."},{"key":"10.1016\/j.jval.2017.02.001_bib19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2307\/2532051","article-title":"A concordance correlation coefficient to evaluate reproducibility","volume":"45","author":"Lawrence","year":"1989","journal-title":"Biometrics"},{"key":"10.1016\/j.jval.2017.02.001_bib20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/hec.1175","article-title":"Comparison of alternative methods of collection of service use data for the economic evaluation of health care interventions","volume":"16","author":"Byford","year":"2007","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2017.02.001_bib21","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1076\/jcen.23.5.695.1249","article-title":"The precision of reliability and validity estimates re-visited: distinguishing between clinical and statistical significance of sample size requirements","volume":"23","author":"Cicchetti","year":"2001","journal-title":"J Clin Exp Neuropsychol"},{"key":"10.1016\/j.jval.2017.02.001_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/fampra\/cmi027","article-title":"A comparison of two methods of collecting economic data in primary care","volume":"22","author":"Patel","year":"2005","journal-title":"Fam Pract"},{"key":"10.1016\/j.jval.2017.02.001_bib23","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40273-014-0193-3","article-title":"A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials","volume":"32","author":"Faria","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2017.02.001_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","article-title":"Cost-effectiveness analysis alongside clinical trials II\u2014an ISPOR Good Research Practices Task Force report","volume":"18","author":"Ramsey","year":"2015","journal-title":"Value Health"}],"updated-by":[{"DOI":"10.1016\/j.jval.2018.03.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000}}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301517301122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301517301122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T05:05:20Z","timestamp":1570770320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301517301122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1098301517301122"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2017.02.001","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jval.2018.03.001","asserted-by":"object"}]},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Comparison of Different Approaches for Costing Medication Use in an Economic Evaluation","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2017.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}